DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
CD200 is up-regulated in R6/1 transgenic mouse model of Huntington's disease
In Huntington’s disease (HD), striatal medium spiny neurons (MSNs) are particularly sensitive to the presence of a CAG repeat in the huntingtin (HTT) gene. However, there are many evidences that cells from the peripheral immune system and central nervous system (CNS) immune cells, namely microglia, play an important role in the etiology and the progression of HD. However, it remains unclear whether MSNs neurodegeneration is mediated by a non-cell autonomous mechanism. The homeostasis in the healthy CNS is maintained by several mechanisms of interaction between all brain cells. Neurons can control microglia activation through several inhibitory mechanisms, such as the CD200–CD200R1 interaction. Due to the complete lack of knowledge about the CD200–CD200R1 system in HD, we determined the temporal patterns of CD200 and CD200R1 expression in the neocortex, hippocampus and striatum in the HD mouse models R6/1 and HdhQ111/7 from pre-symptomatic to manifest stages. In order to explore any alteration in the peripheral immune system, we also studied the levels of expression of CD200 and CD200R1 in whole blood. Although CD200R1 expression was not altered, we observed and increase in CD200 gene expression and protein levels in the brain parenchyma of all the regions we examined, along with HD pathogenesis in R6/1 mice. Interestingly, the expression of CD200 mRNA was also up-regulated in blood following a similar temporal pattern. These results suggest that canonical neuronal–microglial communication through CD200–CD200R1 interaction is not compromised, and CD200 up-regulation in R6/1 brain parenchyma could represent a neurotrophic signal to sustain or extend neuronal function in the latest stages of HD as pro-survival mechanism., This study was supported by grants from
the Ministerio de Ciencia, Innovación y
Universidades (Spain), (RTI2018-099001-B-I00 to
JMC); Instituto de Salud Carlos III, Ministerio de
Ciencia, Innovacio´n y Universidades and European
Regional Development Fund (ERDF) [CIBERNED
and RETICS (Red de Terapia Celular, RD16/0011/
0012 to JMC)], Spain; Generalitat de Catalunya (2017SGR-1408 to J. M. C.), Spain; the CHDI
Foundation (A12076 to JMC), USA; and ADVANCE
(CAT) with the support of ACCIO´ (Catalonia Trade
& Investment; Generalitat de Catalunya) and the
European Community under the Catalonian ERDF
operational program 2014-2020], Spain. T